MetaCap

Champions Oncology (CSBR) vs Tenaya Therapeutics (TNYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Champions Oncology (CSBR) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 35.9% versus a loss of 76.7%. Over five years, CSBR leads with a -53.0% price change compared with -98.5% for TNYA. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $60.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CSBR-35.89%TNYA-76.70%
+20%-31%-81%
Nov 21, 20251 yearNov 20, 2026
CSBR-53.68%TNYA-98.68%
+30%-37%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CSBR versus TNYA key metrics
MetricCSBRTNYA
Share price$4.34$0.2866
Market cap$60.41M$65.32M
1-day change-1.36%-3.99%
YTD return-37.19%-59.75%
1-year return-35.89%-76.70%
5-year return-52.98%-98.50%
Forward P/E43.40—
EPS (TTM)$-0.07$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$59.42M—
Revenue growth (YoY)+4.36%—
Net income (latest FY)$-1.18M$-90.60M
Gross margin48.00%—
Operating margin-1.92%—
Net margin-1.98%—
52-week high$8.31$1.46
52-week low$4.34$0.28
Distance from 52-week high-47.77%-80.37%
Analyst consensus—none
Avg. price target upside—+1016.54%
Average volume9.71K2.96M
Shares outstanding13.92M227.93M
Employees21470
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CSBR has outperformed TNYA by 40.8 percentage points over the past year.

About Champions Oncology

CSBR stock →

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees

About Tenaya Therapeutics

TNYA stock →

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees

CSBR vs TNYA FAQ

Which is bigger, Champions Oncology or Tenaya Therapeutics?

Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $60.41M for Champions Oncology (CSBR).

Which stock has performed better over the past year, CSBR or TNYA?

CSBR returned -35.89% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.

Are Champions Oncology and Tenaya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons